<DOC>
	<DOCNO>NCT02337725</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TVP-1012 ( 1 mg/day ) administer Japanese patient early Parkinson 's disease .</brief_summary>
	<brief_title>A Phase 3 Study TVP-1012 ( 1 mg ) Early Parkinson 's Disease Patients</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , parallel-group , phase 3 study evaluate efficacy safety TVP-1012 Japanese participant early Parkinson 's disease . The study period consist 28-week trial period . The participant fulfill inclusion criterion meet exclusion criterion enrol , randomize 1:1 ratio either 1 mg TVP-1012 placebo group . In treatment group , participant receive either 1 mg TVP-1012 placebo daily double-blinded manner .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>The participant diagnosis Parkinson 's disease least two follow sign : rest tremor , akinesia/hypokinesia , muscle rigidity . The participant Movement Disorder SocietyUnified Parkinson 's Disease Rating Scale ( MDSUPDRS ) Part II + Part III total score &gt; =14 . The participant Modified Hoehn &amp; Yahr stage 1 3 The participant Parkinson 's disease diagnose within 5 year The participant outpatient either sex age &gt; = 30 &lt; 80 year . The participant unstable systemic disease . The participant MiniMental State Examination ( MMSE ) score &lt; = 24 The participant major depression severe depression , clinically significant psychiatric disease . The participant history clinically significant hypertension reaction associate ingestion tyraminerich food . The participant receive neurosurgical intervention Parkinson 's disease ( e.g. , pallidotomy , thalamotomy , deep brain stimulation ) . The participant receive transcranial magnetic stimulation within 6 month The participant receive amantadine anticholinergic medication &gt; = 180 day . The participant receive selegiline , levodopacontaining product dopamine agonist &gt; = 90 day . The participant receive selegiline , pethidine , tramadol , reserpine methyldopa within 90 day . The participant receive levodopacontaining product , dopamine agonist , amantadine anticholinergic drug within 30 day . The participant receive psychoneurotic agent antiemetic medication dopamine agonist within 14 day . However , participant receive quetiapine domperidone stable dose regimen &gt; = 14 day may include study . The participant previously receive catecholOmethyltransferase ( COMT ) inhibitor , droxidopa , zonisamide istradefylline . The participant require take excluded medication treatment . The participant whose diagonosis Parkinson 's disease rule elective dopamine transporter scintigraphy . The participant laboratory data meeting follow start : Creatinine &gt; = 2 x upper limit normal ( ULN ) Total bilirubin &gt; = 2 x ULN ALT AST &gt; = 1.5 x ULN ALP &gt; = 3 x ULN The participant receive excludeded medication treatment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>